MA35107B1 - Composition pharmaceutique antihypertensive - Google Patents

Composition pharmaceutique antihypertensive

Info

Publication number
MA35107B1
MA35107B1 MA36404A MA36404A MA35107B1 MA 35107 B1 MA35107 B1 MA 35107B1 MA 36404 A MA36404 A MA 36404A MA 36404 A MA36404 A MA 36404A MA 35107 B1 MA35107 B1 MA 35107B1
Authority
MA
Morocco
Prior art keywords
pharmaceutical composition
antihypertensive pharmaceutical
pharmaceutically acceptable
antihypertensive
amlodipine
Prior art date
Application number
MA36404A
Other languages
English (en)
Inventor
Seung Ho Kim
Ji Han Kim
Kyung Sang Yu
In Jin Jang
Sang Goo Shin
Seo Hyun Yoon
Joo Youn Cho
Tae Eun Kim
So Jeong Yi
Soo Heui Paik
Yong Ha Chi
Joo Han Lee
Kyung Wan Nam
Je Hak Kim
Original Assignee
Boryung Pharm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47006840&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA35107(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boryung Pharm filed Critical Boryung Pharm
Publication of MA35107B1 publication Critical patent/MA35107B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une composition pharmaceutique antihypertensive contenant du fimasartan, l'un de ses sels pharmaceutiquement acceptables, solvates ou hydrates en tant que bloqueur du récepteur de l'angiotensine ii; et de l'amlodipine, l'un de ses isomères, sels pharmaceutiquement acceptables, solvates ou hydrates en tant que bloqueur des canaux calciques.
MA36404A 2011-04-12 2013-11-08 Composition pharmaceutique antihypertensive MA35107B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20110033856 2011-04-12
PCT/KR2011/005754 WO2012141385A1 (fr) 2011-04-12 2011-08-08 Composition pharmaceutique antihypertensive

Publications (1)

Publication Number Publication Date
MA35107B1 true MA35107B1 (fr) 2014-05-02

Family

ID=47006840

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36404A MA35107B1 (fr) 2011-04-12 2013-11-08 Composition pharmaceutique antihypertensive

Country Status (20)

Country Link
US (1) US8765776B2 (fr)
JP (1) JP5782178B2 (fr)
AU (1) AU2011365756B2 (fr)
BR (1) BR112013025222B8 (fr)
CA (1) CA2832758C (fr)
CL (1) CL2013002905A1 (fr)
CO (1) CO6821940A2 (fr)
CR (1) CR20130526A (fr)
EA (1) EA024096B1 (fr)
EC (1) ECSP13012962A (fr)
GT (1) GT201300241A (fr)
MA (1) MA35107B1 (fr)
MX (1) MX341450B (fr)
MY (1) MY160432A (fr)
NI (1) NI201300106A (fr)
PE (1) PE20141049A1 (fr)
SG (1) SG194162A1 (fr)
UA (1) UA110244C2 (fr)
WO (1) WO2012141385A1 (fr)
ZA (1) ZA201307593B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA024096B1 (ru) 2011-04-12 2016-08-31 Борюн Фармасьютикал Ко., Лтд. Противогипертоническая фармацевтическая композиция
KR101490329B1 (ko) * 2012-10-12 2015-02-04 보령제약 주식회사 피마살탄 포타슘염의 일수화물 결정, 그 제조방법, 및 그를 포함하는 약제학적 조성물
KR20140096514A (ko) * 2013-01-28 2014-08-06 보령제약 주식회사 암 예방 또는 치료용 조성물
AU2014230182B2 (en) * 2013-03-14 2016-12-22 Boryung Pharmaceutical Co., Ltd. Pharmaceutical combination drug
KR20150041223A (ko) * 2013-10-04 2015-04-16 보령제약 주식회사 피마살탄을 포함하는 허혈성 뇌질환 예방 또는 치료용 약학적 조성물
CN105395552A (zh) * 2014-09-05 2016-03-16 南京华威医药科技开发有限公司 一种含非马沙坦及其盐的固体制剂
KR101545268B1 (ko) * 2015-02-05 2015-08-20 보령제약 주식회사 정제 및 이의 제조방법
WO2017091041A1 (fr) * 2015-11-26 2017-06-01 보령제약 주식회사 Nouveau sel de fimasartan
US11452690B1 (en) 2021-01-27 2022-09-27 ECI Pharmaceuticals, LLC Oral liquid compositions comprising amlodipine besylate and methods of using the same
CN112704667A (zh) * 2021-02-24 2021-04-27 施慧达药业集团(吉林)有限公司 含苯磺酸左氨氯地平水合物的组合物及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK161312C (da) 1982-03-11 1991-12-09 Pfizer Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden
CA1334092C (fr) 1986-07-11 1995-01-24 David John Carini Imidazoles bloquant les recepteurs de l'angiotensine ii
EP0733366B1 (fr) 1988-01-07 1998-04-01 E.I. Du Pont De Nemours And Company Compositions pharmaceutiques comprenant des imidazoles comme antagonistes d'angiotensine II et des diurétiques
KR100300566B1 (ko) 1994-09-17 2001-11-22 조생현 피리미디논유도체와그의제조방법및용도
KR19990081093A (ko) * 1998-04-25 1999-11-15 조생현 피리미디논 화합물, 이를 함유하는 약제학적 조성물 및 이의제조방법
SK285863B6 (sk) * 1998-07-10 2007-10-04 Novartis Ag Kombinovaná farmaceutická kompozícia obsahujúca AT1-antagonistu valsartan a amlodipín
FR2783422A1 (fr) 1998-09-21 2000-03-24 Sanofi Sa Composition pharmaceutique contenant un antagoniste des recepteurs at1 de l'angiotensine ii et un antiagregant plaquettaire
KR100617953B1 (ko) 2000-03-23 2006-08-30 보령제약 주식회사 피리미디논 화합물 및 이의 염의 제조방법
AU2001292386B2 (en) * 2001-09-21 2006-06-22 Boryung Pharmaceutical Co., Ltd. Method for preparing pyrimidinone compound and pharmaceutically acceptable salts thereof
KR100521980B1 (ko) 2002-10-10 2005-10-17 보령제약 주식회사 피리미디논 화합물 및 이의 염의 삼수화물의 제조 방법
BRPI0612674B8 (pt) * 2005-06-27 2021-05-25 Daiichi Sankyo Co Ltd preparação farmacêutica, uso de um antagonista do receptor de angiotensina ii e um bloqueador do canal de cálcio
KR100888131B1 (ko) * 2006-10-10 2009-03-11 한올제약주식회사 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제
KR20100048137A (ko) 2008-10-30 2010-05-11 현대약품 주식회사 혈압 강하용 약학 조성물
KR101058284B1 (ko) 2010-01-22 2011-08-22 보령제약 주식회사 2-(2-ｎ-부틸-4-히드록시-6-메틸-피리미딘-5-일)-Ｎ,Ｎ-디메틸아세트아미드의 신규한 제조방법
EA024096B1 (ru) 2011-04-12 2016-08-31 Борюн Фармасьютикал Ко., Лтд. Противогипертоническая фармацевтическая композиция

Also Published As

Publication number Publication date
CL2013002905A1 (es) 2014-04-11
JP5782178B2 (ja) 2015-09-24
BR112013025222A2 (pt) 2016-12-27
US20120264772A1 (en) 2012-10-18
US8765776B2 (en) 2014-07-01
PE20141049A1 (es) 2014-09-05
NI201300106A (es) 2014-05-05
AU2011365756B2 (en) 2015-07-30
CO6821940A2 (es) 2013-12-31
GT201300241A (es) 2015-08-13
CR20130526A (es) 2014-03-11
UA110244C2 (en) 2015-12-10
JP2014510785A (ja) 2014-05-01
EA024096B1 (ru) 2016-08-31
WO2012141385A1 (fr) 2012-10-18
MX341450B (es) 2016-08-19
EA201370219A1 (ru) 2014-02-28
CA2832758A1 (fr) 2012-10-18
MX2013011879A (es) 2014-03-31
ZA201307593B (en) 2015-04-29
MY160432A (en) 2017-03-15
SG194162A1 (en) 2013-11-29
ECSP13012962A (es) 2013-11-29
BR112013025222B8 (pt) 2020-05-05
CA2832758C (fr) 2015-12-15
AU2011365756A1 (en) 2013-10-31
BR112013025222B1 (pt) 2020-03-17

Similar Documents

Publication Publication Date Title
MA35107B1 (fr) Composition pharmaceutique antihypertensive
TW200833370A (en) Pharmaceutical composition containing low substituted hydroxypropylcellulose
PT1940839E (pt) Inibidores de piridopirimidinona pi3k alfa
EA201490161A1 (ru) Соединения - ингибиторы сигналинга, опосредуемого рецептором notch
EA201101583A1 (ru) Ингибиторы pi3 киназы или mtor
EA200970156A1 (ru) Пиридизиноновые производные
EA201101398A1 (ru) Замещенные пиперидины в качестве антагонистов ccr3
EA201290183A1 (ru) Бензодиазепиновый ингибитор бромодомена
MX2013005826A (es) Benzoxazepinas como inhibidores de fosfatidilinositol 3-cinasa/objetivo de rapamicina en mamiferos (p13k/mtor) y metodos de uso y fabricacion.
EA201390163A1 (ru) Гетеробициклические производные в качетстве ингибиторов hcv
UA100877C2 (ru) Замещенные спироциклические производные пиперидина как лиганды рецепторов гистамина-3 (h3)
TR201907381T4 (tr) Beta-laktamil fenilalanin, sistein ve serin vazopressin antagonisti.
DE602006018713D1 (de) Als agonisten für den nikotinischen acetylcholinrezeptor geeignete azabicycloalkanderivate
BRPI0917661B8 (pt) produto, composição farmacêutica e uso da combinação de macitentan com um composto que é dotado de propriedades agonistas do receptor de prostaciclina
MX353209B (es) Antagonistas d2, metodos de sintesis y metodos de uso.
MA39164A1 (fr) Forme de sel cristalline de (s)-(2-(6-chloro-7-méthyl-1 h-benzo[d]imidazol- 2-yl)-2-méthylpyrrolidin-1-yl)(5-méthoxy-2-(2h-1,2,3-triazol-2-yl)phényl)méthanone comme antagoniste des récepteurs à l'oréxine
EA201001353A1 (ru) Гидробромид ивабрадина
EA201070532A1 (ru) Новые непептидные производные соединения в качестве b1 антагонистов брадикинина
ATE461172T1 (de) Azetidinderivate als antagonisten des muskarinrezeptors
IL206611A0 (en) Novel imidazolinylmethyl aryl sulfonamides
EA201170549A1 (ru) Комбинированная терапия с использованием блокаторов рецепторов ангиотензина и антагонистов рецепторов вазопрессина
MX2010007928A (es) Imidazolinilmetil aril sulfonamidas novedosas.
BRPI0907495A2 (pt) sulfonamidas de imidazolinilmetil arila
MA50899B1 (fr) Composés utiles pour l'inhibition de cdk7
TN2013000515A1 (en) Notch pathway signaling inhibitor compound